We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DEMANT:OMXCOPDemant A/S Analysis

Data as of 2026-03-15 - not real-time

DKK 188.10

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at DKK 188.1, just above the 20‑day SMA of 188.06 but well below the 50‑day (203.57) and 200‑day (232.20) averages, indicating a short‑term pull‑back within a broader bearish trend. Momentum is mixed: the RSI sits at 45, suggesting neutral pressure, while the MACD histogram turned positive and the MACD line crossed above its signal, a bullish technical signal. Price remains above the identified support of 175 and below the resistance near 199, giving a modest upside window on the near term.
Fundamentally, Demant delivers solid revenue growth of 3.4% and strong gross margins (~75%), yet its profit margin is modest at 6.7% and debt levels are high, with a debt‑to‑equity ratio exceeding 200%. The DCF‑derived fair value of 151.5 is well under the current market price, implying the stock is overvalued relative to intrinsic estimates. Despite a healthy ROE of 24% and robust free cash flow, the lack of dividend payout and a forward PE of 12.75 point to a value‑oriented profile, while analyst consensus remains a “buy” with a median target near DKK 230.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD crossover
  • Price above 20‑day SMA and near support
  • Neutral RSI offering upside potential

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Valuation gap between market price and DCF fair value
  • Strong operating and free cash flow
  • Elevated leverage increasing financial risk

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Current price significantly above intrinsic fair value
  • High debt‑to‑equity ratio limiting future flexibility
  • Potential regulatory headwinds in the medical‑device sector

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin6.73%
P/E Ratio16.8
ROE24.20%
ROA6.93%
Debt/Equity211.59
P/B Ratio4.0
Op. Cash FlowDKK4.0B
Free Cash FlowDKK3.3B
Industry P/E26.2

Technical Analysis

TrendBearish
RSI45.1
SupportDKK 175.00
ResistanceDKK 199.00
MA 20DKK 188.06
MA 50DKK 203.57
MA 200DKK 232.20
MACDBullish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueDKK 151.50
Target PriceDKK 232.17
Upside/Downside23.43%
GradeOvervalued
TypeValue

Risk Assessment

Beta0.43
Volatility48.56%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.